Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
<br><strong>Background: </strong>Vedolizumab is a gut‐selective antibody to α4β7 integrin approved to treat moderate‐to‐severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increased risk of mal...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Jezik: | English |
| Izdano: |
Wiley
2019
|